Lombard Odier Asset Management (Switzerland) Sa Intellia Therapeutics, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $609,190 - $819,937	18,294 Added 29.99%	79,298 $2.96 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $232,503 - $309,170	-4,312 Reduced 6.6%	61,004 $3.41 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $530,122 - $1.05 Million	-13,773 Reduced 17.41%	65,316 $3.38 Million
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $1.99 Million - $4.07 Million	-34,222 Reduced 30.2%	79,089 $5.75 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $3.58 Million - $4.91 Million	-35,495 Reduced 23.85%	113,311 $13.4 Million
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $846,506 - $1.13 Million	-6,395 Reduced 4.12%	148,806 $20 Million
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $7.78 Million - $20.7 Million	-127,752 Reduced 45.15%	155,201 $25.1 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $13.2 Million - $23.7 Million	282,953 New	282,953 $22.7 Million

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

12.3M
Shares

$149 Million
2.39% of portfolio
Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$117 Million
0.0% of portfolio
Black Rock Inc. New York, NY

9.6M
Shares

$117 Million
0.0% of portfolio
State Street Corp Boston, MA

5.14M
Shares

$62.6 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.95M
Shares

$60.3 Million
3.75% of portfolio

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account